Drug Product Optimization

Unique and innovative formulations help our customers achieve their drug program goals. Find out about our rapid formulation optimization programs.

Translational Pharmaceutics® Contact Us

Rapid 'Make-Test' cycles enabled by Translational Pharmaceutics®.

Our unique approach to drug product optimization:

Saves time by reducing the chemistry, manufacturing, and controls (CMC) data package needed for your clinical assessments
Maximizes flexibility by allowing you to fine-tune formulation compositions
Increases the potential for success by facilitating decisions based on clinical data
Conserves the active pharmaceutical ingredient (API) by removing drug product scale-up from the critical path

Translational Pharmaceutics® has supported our customers through:

Evaluation and selection of solubilization technologies • Optimization of modified-release systems
Improvement of taste, palatability, and acceptability for pediatric indications
Changing routes of delivery
Development of combination products
Understanding quality by design (QbD) of product and process variables

What our customers say

Our team works with our customers to design a customized program to deliver your objectives in the most timely and cost-efficient way. We have completed more than 300 formulation optimization programs, involving the clinical evaluation of more than 1,000 formulations.

We are very excited with the results of our first human study... We have been able to leverage Quotient Sciences’ Translational Pharmaceutics® platform to gain rapid access to the clinic, helping deliver these favorable results in a smooth and rapid fashion.

Dr. Simon Yaxley

Director and Co-founder , Oxilio

Leveraging an integrated compounding pharmacy approach under the Translational Pharmaceutics® platform saved us over a million dollars because we didn’t need to invest in scaling up peptide synthesis. We were able to make just the right amount of drug product needed to achieve the results we were looking for.

Russell Potterfield

CEO and Executive Chairman , Endevica Bio

I knew that traditional manufacture and release would make it impossible for us to clinically determine the correct nafamostat component of our drug product. Quotient Sciences explained to me how their Translational Pharmaceutics® platform could reduce our development timeline by defining a design space for ER release rate, ER/IR ratio, and nafamostat dose. Additionally, they could integrate real-time adaptive manufacturing with clinical testing to rapidly test the variables within the design space and optimize the nafamostat formulation.

Lynn Kirkpatrick

CEO , Ensysce Biosciences

Go further with Quotient Sciences

Case Studies

Discover how we've helped pharma and biotech organizations successfully meet their milestones.

See Examples

Translational Pharmaceutics®

Accelerates drug development by integrating real-time cGMP manufacturing and clinical activities.

Explore More

Humanity can't afford to wait, so neither can we.

Let's talk